De-risking the 18-24 Month Path to IND with NHP Toxicology Programs

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

De-risking the 18-24 Month Path to IND with NHP Toxicology Programs

CELL & GENE | RNA | BIOLOGICS

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Proven Intelligence in Preclinical Toxicology.

Executive Summary

The 18-24 month timeline from candidate selection to IND submission is a period of high operational risk. For next-generation therapies, a generic, template-based preclinical toxicology program is insufficient and often introduces delays. This asset outlines a tailored scientific strategy for designing and executing robust IND-enabling toxicology studies in nonhuman primate (NHP) models. It focuses on mitigating risk through immunologically relevant model selection, integrated supply chain security, and modality-specific study design informed by a deep scientific pedigree in AAV and other complex vectors.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Frequently Asked Questions

How does Franklin Biolabs ensure NHP model availability to avoid delays in IND-enabling toxicology studies?

We mitigate timeline risk through a strategic integration with the Bioculture Group. This provides a secure, integrated supply chain of Mauritian origin SPF cynomolgus macaques, managed through U.S.-based quarantine and fully compliant regulatory import clearance. This direct oversight ensures predictable study initiation for sponsors based in the US, Switzerland, and the EU.

What is the primary cause of unexpected findings in NHP toxicology programs for AAV vectors?

Unforeseen toxicities often arise from a mismatch between the vector, dose, route of administration, and the specific biology of the NHP model. As demonstrated in prior AAV9 studies, dose-dependent findings can emerge that require careful clinical monitoring (PMID: 30073179). A tailored program, designed from first principles for each unique therapeutic, is the most effective method for minimizing clinical risk.

Can a single preclinical data package support submissions to both the FDA and European authorities like Swissmedic or the EMA?

Yes. We design IND-enabling toxicology studies with global regulatory expectations in mind, adhering to harmonized ICH guidelines. The resulting data packages and reports are structured to support concurrent Investigational Medicinal Product Dossier (IMPD) and IND submissions, facilitating a coordinated global development strategy.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

A Data-Driven Approach to Preclinical Design

Achieving a successful IND submission within an 18-24 month window depends on a preclinical program built from scientific rationale. The core team of principal scientists at Franklin Biolabs has maintained a 100% successful IND rate since 2019, a track record established prior to our formal launch in 2024. This success is rooted in the understanding that each next-generation therapy presents a unique biological challenge.

A data-driven preclinical strategy is tailored to the specific asset modality and target indication. This involves a rigorous evaluation of the vector platform, transgene product, and intended route of administration to define the most relevant safety endpoints. Best practices for gene therapy programs emphasize this level of preclinical optimization to inform regulatory approval pathways (PMID: 25654329).

The Role of Immunologically Relevant NHP Models

For many novel biologic platforms, the nonhuman primate is the most translationally relevant species for evaluating safety. Selecting an NHP model with an immune system that closely mirrors the human response is fundamental to generating predictive data.

Key considerations for NHP study design include:

  • Dose-Response Characterization: Determining a safe starting dose requires meticulous evaluation of dose-dependent toxicities. For instance, studies involving direct CNS administration of AAV9 vectors have revealed dose-dependent pleocytosis and sensory neuron effects, highlighting the need for specific monitoring strategies in subsequent clinical trials.

  • Intensive In-Life Monitoring: A robust toxicology program requires detailed clinical observations and specialized functional assessments tailored to the therapeutic’s mechanism and delivery route. This proactive monitoring is designed to identify subtle, on-target or off-target physiological effects before they become confounding variables.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Supply Chain Security and Animal Welfare

Program delays are frequently caused by logistical and supply chain failures. Our integration with the Bioculture Group provides sponsors with a secure and fully traceable supply of Mauritian origin SPF cynomolgus macaques. This integrated supply chain, complete with U.S.-based quarantine services, removes a significant variable from project timelines.

High-quality, reproducible data depends on superior animal welfare. Our >100,000 sq ft facility operates in compliance with USDA regulations, and our partners, including the Bioculture Group, maintain AAALAC accreditation. We are committed to the “3Rs” principle of Replacement, Reduction, and Refinement. This includes enhanced housing conditions and cognitive enrichment programs during the in-life phase of NHP studies. Our approach to animal welfare is detailed further here:.

This focus on scientific rigor, supply chain stability, and animal welfare underpins our ability to execute complex preclinical programs that deliver clear, actionable data for regulatory submissions.

Our work in this area is a core component of our broader Preclinical and Translational Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities